A5086304947- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- RNA Research and Splicing
- Lung Cancer Treatments and Mutations
- RNA modifications and cancer
- Glioma Diagnosis and Treatment
- RNA and protein synthesis mechanisms
- Gastrointestinal Tumor Research and Treatment
- Epigenetics and DNA Methylation
- Gastric Cancer Management and Outcomes
- Lung Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Renal cell carcinoma treatment
- Cutaneous Melanoma Detection and Management
- Melanoma and MAPK Pathways
- Multiple and Secondary Primary Cancers
- Prostate Cancer Treatment and Research
- Cancer-related molecular mechanisms research
- Lung Cancer Research Studies
- Cancer Diagnosis and Treatment
- Scientific Computing and Data Management
- Multiple Myeloma Research and Treatments
- Cancer Cells and Metastasis
- HER2/EGFR in Cancer Research
Hospital Clínic de Barcelona
2021-2025
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2023-2025
Centre for Genomic Regulation
2016-2024
Hospital General de Granollers
2022-2023
Hospital Universitari Germans Trias i Pujol
2014-2022
Vall d'Hebron Institut de Recerca
2017-2020
Universitat Pompeu Fabra
2016-2020
Institut Català d'Oncologia
2014-2017
Barcelona Institute for Science and Technology
2016
Universitat de Barcelona
2016
Abstract Over the past decades, consistent studies have shown that race/ethnicity a great impact on cancer incidence, survival, drug response, molecular pathways and epigenetics. Despite influence of in outcomes its health care quality, comprehensive understanding racial/ethnic inclusion oncological research has never been addressed. We therefore explored composition samples/individuals included fundamental (patient-derived models, biobanks genomics) applied (clinical trials). Regarding...
Abstract Immune-checkpoint inhibitors (ICI) have revolutionized the therapeutic landscape of cancer. However, optimal patient selection is still an unmet need. One-hundred-forty-six patients with metastatic cancer candidates to ICI at Hospital Clinic Barcelona Clinical Trials Unit were prospectively recruited in this observational study. Blood samples collected different timepoints, baseline LIPI score calculated and pre-ICI archived tissues retrieved evaluate PD-L1, tumor-infiltrating...
PURPOSE Ethnic diversity in cancer research is crucial as race/ethnicity influences incidence, survival, drug response, molecular pathways, and epigenetic phenomena. In 2018, we began a project to examine racial/ethnic research, with commitment review these disparities every 4 years. This report our second assessment, detailing the present state of genomics clinical trials. METHODS To study inclusion genomics, extracted ethnic records from all data sets available at cBioPortal (n = 125,128...
Abstract Introduction Immune check-point inhibitors (ICI) were a major breakthrough in cancer care, but optimal patient selection remains elusive most tumors. Methods Overall 173 adult patients with metastatic solid tumors candidates to ICI clinical trials at our Institution prospectively recruited. Blood samples collected cycle 1 (C1D1) and 2 (C2D1) until the occurrence of progressive disease (PD). C1D1 LIPI, RMH, PMHI, NLR, dNLR, PIPO GRIm prognostic scores calculated. The primary endpoint...
Electronic laboratory notebooks (ELNs) will probably replace paper (PLNs) in academic research due to their advantages data recording, sharing and security. Despite several reports describing technical characteristics of ELNs over PLNs, no study has directly tested ELN performance among researchers. In addition, the usage tablet-based devices or wearable technology as complements never been explored field. To implement an our biomedical institute, here we first present a comparison six using...
Taxanes are the most active chemotherapy agents in metastatic castration-resistant prostate cancer (mCRPC) patients; yet, resistance occurs almost invariably, representing an important clinical challenge. Taxane-platinum combinations have shown benefit a subset of patients, but mechanistic basis and biomarkers remain elusive. To identify mechanisms response indicators for antitumor efficacy taxane-platinum mCRPC. Transcriptomic data from publicly available mCRPC dataset taxane-exposed...
Cold-inducible RNA binding protein (CIRBP) is a stress-responsive that promotes cancer development and inflammation. Critical to most CIRBP functions its capacity bind posttranscriptionally modulate mRNA. However, transcriptome-wide analysis of mRNA targets in has not yet been performed. Here, we use an ex vivo breast model identify mechanisms. We find transcript levels correlate with subtype are indicator luminal A/B prognosis. Accordingly, overexpression nontumoral MCF-10A cells cell...
Abstract RNA-binding proteins (RBPs) have been relatively overlooked in cancer research despite their contribution to virtually every hallmark. Here, we use RNA interactome capture (RIC) characterize the melanoma RBPome and uncover novel RBPs involved progression. Comparison of RIC profiles a non-tumoral versus metastatic cell line revealed prevalent changes capacities that were not associated with RBP levels. Extensive functional validation selected group 24 using five different vitro...
Scientific data recording and reporting systems are of a great interest for endorsing reproducibility transparency practices among the scientific community. Current research generates large datasets that can no longer be documented using paper lab notebooks (PLNs). In this regard, electronic laboratory (ELNs) could promising solution to replace PLNs promote transparency. We previously analyzed five ELNs performed two survey-based studies implement an ELN in biomedical institute. Among...
Breast cancer (BC) is the leading cause of cancer-associated death among women worldwide. Despite treatment efforts, advanced BC with distant organ metastases considered incurable. A better understanding molecular processes therefore great interest to identify new therapeutic targets. Although large-scale such as The Cancer Genome Atlas (TCGA), have completely redefined drug development, diagnosis, and treatment, additional key aspects tumor biology remain be discovered. In that respect,...
Pancreatic ductal adenocarcinoma is an aggressive form of pancreatic cancer and the fourth leading cause cancer-related death. When possible, curative approaches are based on surgical resection, though not every patient a candidate for surgery. There clinical guidelines management these patients that offer different treatment options depending pathologic characteristics. However, survival rates seen in this kind still low. The CDSE1 gene located upstream NRAS encodes RNA-binding protein...
Colorectal adenocarcinoma (COREAD) is the second most deadly cancer and third frequently encountered malignancy worldwide. Despite efforts in molecular subtyping subsequent personalized COREAD treatments, multidisciplinary evidence suggests separating into colon (COAD) rectal (READ). This new perspective could improve diagnosis treatment of both carcinomas. RNA-binding proteins (RBPs), as critical regulators every hallmark cancer, fulfill need to identify sensitive biomarkers for COAD READ...
More women are diagnosed with breast cancer (BC) than any other type of cancer. Although large-scale efforts have completely redefined cancer, a cure remains unattainable. In that respect, new molecular functions the cell should be investigated, such as post-transcriptional regulation. RNA-binding proteins (RBPs) emerging critical modulators tumorigenesis, but only few clear roles in BC. To recognize putative proteins, we performed integrated silico analyses all human RBPs (n = 1392) three...
RNA-binding proteins are emerging as critical modulators of oncogenic cell transformation, malignancy and therapy resistance. We have previously found that the protein Cold Shock Domain containing E1 (CSDE1) promotes invasion metastasis melanoma, deadliest form skin cancer also a highly heterogeneous disease in need predictive biomarkers druggable targets. Here, we design monoclonal antibody useful for IHC clinical setting use it to evaluate prognosis potential CSDE1 an exploratory cohort...
Abstract BACKGROUND ATP-dependent helicase (ATRX) loss-of-function mutations are a hallmark driver in IDH-mutated astrocytoma, and they usually associated with the loss of P53 presence alternative lengthening telomeres (ALT) phenotype. Inhibition ataxia telangiectasia Rad3-related (ATR), key protein kinase involved response to DNA damage, has shown preclinical synthetic lethality ATRX mutated tumors, more specifically ALT. Preclinical evidence also suggests that IDH mutant tumors show...
e22139 Background: During the last years, new predictive and less frequent biomarkers have emerged in NSCLC, such as ROS1 translocation (ROS1t), HER2 mutations (HER2m) BRAF (BRAFm). We analyze retrospectively frequency, clinical tumor characteristics of NSCLC p TN( EGFR, KRAS ALK wild-type). Methods: The study included data from all consecutive non-squamous non-smokers squamous TN advanced diagnosed at our hospital December 2008 to July 2014. Results: 101 were included. table below...
We extensively characterized a metastatic UPS with 71-month lasting complete response to immunotherapy.
Abstract Background Taxanes are the most active chemotherapy agents in metastatic castration resistant prostate cancer (mCRPC) patients, yet resistance almost invariably occurs representing an important clinical challenge. Taxane-platinum combinations have shown benefit a subset of patients but mechanistic basis and biomarkers remain elusive. Objective To identify mechanisms response for antitumor efficacy taxane-platinum mCRPC. Design, setting, participants Transcriptomic data from publicly...